Cordis Launches Integrated Solutions for Transradial Care
of Radial Solutions, a complete portfolio for transradial interventions. New
to the portfolio is the Cordis RADIALSOURCE(TM) Transradial Access Kit.
RADIALSOURCE(TM) Transradial Sheaths are designed to provide physicians with
atraumatic and smooth access to the radial artery during diagnostic and
interventional procedures and is a result of Cordis’ long standing commitment
to driving innovation.
The rate of transradial procedures (TRA) in cardiovascular interventions
is growing. Several studies have shown lower complication rates associated
with transradial compared to the femoral approach. Cordis, a division of
Johnson & Johnson Medical, is dedicated to providing complete solutions for
cardiovascular interventions. The “Radial Solutions” portfolio, including the
RADIALSOURCE(TM) Transradial Sheaths, diagnostic and guiding catheters has
been created in close cooperation with clinical partners to meet the
requirements for this technique.
TRA offers significant benefits for patients, especially in patients who
are at high risk of bleeding. Completing haemostasis after TRA is simpler as
the artery is superficial and easier to compress, increasing patient comfort.
Cordis Radial Solutions portfolio comprises of Cordis’ well known guiding
and diagnostic catheters with new specific radial shapes, transradial sheath
introducer, guidewires and professional education training.
The RADIALSOURCE(TM) Transradial Sheath incorporates a new tapering
design in conjunction with a lubricious coating, offering the benefits of low
insertion force with a smooth atraumatic entry, while enabling stability
during procedure and ease of removal. Customers will be offered a choice of
kit with a bare metal spring mini guidewire or a polymer-coated mini
Cordis is dedicated to professional education and is committed to
expanding the use of radial approach to improve patient safety through
teaching and tutoring to improve outcomes. “We offer comprehensive training
through our Cordis Cardiac & Vascular Institute programme, conducted in
co-operation with leading interventional cardiologists, who have the goal of
sharing expertise for better patient outcomes,” said
M.D. Worldwide Vice President, Medical Affairs, Cordis Corporation
About Cordis Corporation
For more than 50 years, Cordis Corporation, a Johnson & Johnson company,
has been a worldwide leader in the development and manufacture of
interventional vascular technology. Through the company’s innovation,
research and development, Cordis partners with interventional cardiologists
worldwide to treat millions of patients who suffer from vascular disease.
 RIVAL Trial – Published online (http://www.thelancet.com)